SMOT - ETF AI Analysis
Top Page
VanEck Morningstar SMID Moat ETF (SMOT)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and in recent months, showing positive momentum for investors.
Broad Sector Diversification
Holdings are spread across many sectors, including health care, industrials, consumer stocks, technology, and more, which helps reduce the impact of weakness in any single industry.
Multiple Strong Top Holdings
Several of the largest positions, such as Bio-Techne, Masco, Block, Royalty Pharma, Corteva, and Amcor, have shown strong year-to-date performance, supporting the fund’s overall results.
Negative Factors
Higher Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of the returns are used to cover fees.
Heavy U.S. Concentration
With almost all assets invested in U.S. companies, the ETF offers very limited international diversification and is highly tied to the U.S. market.
Several Weak Top Holdings
Some key positions, including Acuity Brands, IQVIA Holdings, TransUnion, and Stifel Financial, have shown weak year-to-date performance, which can drag on the fund’s returns.
SMOT vs. SPDR S&P 500 ETF (SPY)
AUM337.87M
RegionNorth America
Expense Ratio0.49%
Beta0.86
IssuerVanEck
Inception DateOct 04, 2022
Dividend Yield1.21%
Asset ClassEquity
Index TrackedMorningstar US Small-Mid Cap Moat Focus
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume23,508
30 Day Avg. Volume24,330
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
46.85Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering110
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMOT Summary
The VanEck Morningstar SMID Moat ETF (SMOT) tracks the Morningstar US Small-Mid Cap Moat Focus Index, which looks for smaller and mid-sized U.S. companies with strong competitive advantages, or “moats.” It spreads investments across many sectors, including health care, industrials, and technology, and holds well-known names like Corteva and TransUnion. Someone might invest in SMOT to seek long-term growth and diversify beyond the usual large-company funds. A key risk is that smaller and mid-sized stocks can be more volatile, so the ETF’s value can rise and fall more sharply than the overall market.
How much will it cost me?The VanEck Morningstar SMID Moat ETF (Ticker: SMOT) has an expense ratio of 0.49%, meaning you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on identifying companies with strong competitive advantages or 'moats.'
What would affect this ETF?The VanEck Morningstar SMID Moat ETF could benefit from economic growth and innovation in sectors like technology and consumer cyclical, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as smaller companies often struggle with higher borrowing costs, or if economic uncertainty impacts consumer spending. Its focus on U.S. small and mid-cap stocks provides growth potential but also exposes it to volatility compared to large-cap investments.
SMOT Top 10 Holdings
SMOT leans heavily into U.S. small and mid-cap health care and industrial names, with a few consumer and materials plays rounding out the mix. Royalty Pharma has been a key engine, rising steadily on strong profitability and deal-making, while Corteva adds another pillar of strength with solid, moat-like fundamentals. Bio-Techne has been more of a steady contributor, its momentum offset by concerns about slowing growth. On the weaker side, Acuity Brands and IQVIA have shown mixed, sometimes lagging performance, occasionally acting as a brake on the fund’s otherwise upbeat trajectory.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Bio-Techne | 1.63% | $5.49M | $11.32B | 43.81% | 64 Neutral | |
| IQVIA Holdings | 1.61% | $5.43M | $39.29B | 34.37% | 73 Outperform | |
| Airbnb | 1.61% | $5.43M | $106.33B | 56.13% | 71 Outperform | |
| Acuity Brands | 1.55% | $5.23M | $10.76B | 12.83% | 77 Outperform | |
| Amcor | 1.47% | $4.94M | $22.13B | -2.26% | 73 Outperform | |
| Lamb Weston Holdings | 1.44% | $4.84M | $7.19B | 0.31% | 61 Neutral | |
| Masco | 1.42% | $4.80M | $15.28B | 8.45% | 53 Neutral | |
| Stifel Financial | 1.42% | $4.79M | $12.60B | 12.95% | 75 Outperform | |
| Block | 1.41% | $4.75M | $47.46B | 8.15% | 72 Outperform | |
| Royalty Pharma | 1.40% | $4.72M | $32.65B | 60.18% | 79 Outperform |
SMOT Technical Analysis
Positive
―
Price Trends
39.33
Positive
38.08
Positive
37.17
Positive
Market Momentum
0.55
Negative
66.67
Neutral
93.67
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SMOT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 40.11, equal to the 50-day MA of 39.33, and equal to the 200-day MA of 37.17, indicating a bullish trend. The MACD of 0.55 indicates Negative momentum. The RSI at 66.67 is Neutral, neither overbought nor oversold. The STOCH value of 93.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMOT.
SMOT Peer Comparison
Comparison Results
Performance Comparison
SMOT
VanEck Morningstar SMID Moat ETF
41.27
6.00
17.01%
RSMC
Rockefeller U.S. Small-Mid Cap ETF
―
―
―
MSSM
Morgan Stanley Pathway Small-Mid Cap Equity ETF
―
―
―
GRNJ
Fundstrat Granny Shots US Small- & Mid-Cap ETF
―
―
―
ISMD
Inspire Small/Mid Cap Impact ETF
―
―
―
SMIZ
Zacks Small/Mid Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents